Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

INtestinal Tissue ENgineering Solution

Objetivo

Short Bowel Syndrome (SBS) is a condition that occurs when part or the entire small intestine is missing or has been removed during surgery. This condition renders the bowel incapable of fulfilling its nutritional function (intestinal failure). There is no cure for SBS. Parenteral (intravenous) nutrition (PN) and bowel transplantation are currently the preferred options for nutrition in children and adults who have lost their bowel. PN offers a low survival rate, compromised quality of life, and the economic cost for each patient is estimated to be 55,000 euro/year. Small intestinal transplant is also an option with one-year and 4-year survival rates of 90% and 60% respectively. However, because of the shortage of organs, high mortality, the severe side effects of immunosuppression and low quality of life, this is still a sub-optimal solution. The objective of this programme is to deliver a functional bowel reconstruction option to patients with SBS through an autologous tissue engineering strategy, overcoming the shortage of organs, and avoiding the need for immunosuppression. It will be achieved by identifying the best autologous cell source; providing the ideal scaffold; engineering functional intestinal mucosa for transplantation and engaging with patients, scientists and public. The work is designed to lead directly to a clinical trial for the application of the optimal protocol for tissue-engineered intestinal mucosa. The consortium is uniquely positioned to complete this ambitious effort as we have an internationally pre-eminent, multi-disciplinary team, which possesses a combination of expertise from basic molecular biology, engineering, and surgery, combining knowledge from universities, hospitals and industry. Importantly we are one of the few groups in the world with experience, infrastructure, and track record to translate regenerative medicine solutions to patients, including true clinical translation of tissue engineered organs.

Convocatoria de propuestas

H2020-PHC-2014-2015

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-PHC-2015-two-stage

Régimen de financiación

RIA - Research and Innovation action

Coordinador

UNIVERSITY COLLEGE LONDON
Aportación neta de la UEn
€ 1 569 546,00
Dirección
GOWER STREET
WC1E 6BT London
Reino Unido

Ver en el mapa

Región
London Inner London — West Camden and City of London
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 1 569 548,25

Participantes (8)